VOR

MKT CAP:$97M

Vor Biopharma Inc.

Market Cap

$97M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$14.62+$2.98 (+25.60%)

Apr 23, 2026

Company Details

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) an...

CEO

Jean-Paul Kress

IPO Date

Feb 5, 2021

Website

www.vorbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$696M

EPS (Diluted)

-$333.53

Free Cash Flow

-$144M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$70.50

Q4 2025

Mar 30, 2026

$0EPS $44.50

Q3 2025

Nov 13, 2025

$0EPS -$121.63

Q2 2025

Aug 12, 2025

$0EPS -$251.20

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$23M
Q2 22	$0	$0	-$22M
Q3 22	$0	$0	-$24M
Q4 22	$0	$0	-$25M
Q1 23	$0	$0	-$30M
Q2 23	$0	$0	-$32M
Q3 23	$0	$0	-$35M
Q4 23	$0	-$892.0K	-$28M
Q1 24	$0	-$943.0K	-$32M
Q2 24	$0	-$900.0K	-$29M
Q3 24	$0	$0	-$29M
Q4 24	$0	-$865.0K	-$31M
Q1 25	$0	$0	-$33M
Q2 25	$0	$0	-$274M
Q3 25	$0	$0	-$28M
Q4 25	$0	-$23.0K	-$36M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$23M	-$25M
Q2 22	-$25M	-$31M
Q3 22	-$19M	-$19M
Q4 22	-$18M	-$19M
Q1 23	-$24M	-$24M
Q2 23	-$24M	-$24M
Q3 23	-$28M	-$28M
Q4 23	-$24M	-$24M
Q1 24	-$30M	-$31M
Q2 24	-$22M	-$22M
Q3 24	-$23M	-$23M
Q4 24	-$24M	-$24M
Q1 25	-$31M	-$31M
Q2 25	-$35M	-$35M
Q3 25	-$54M	-$54M
Q4 25	-$23M	-$23M

Capital Expenditures

Quarter	CapEx
Q1 22	$2M
Q2 22	$6M
Q3 22	$298.0K
Q4 22	$321.0K
Q1 23	$94.0K
Q2 23	$399.0K
Q3 23	$465.0K
Q4 23	$111.0K
Q1 24	$114.0K
Q2 24	$9.0K
Q3 24	$34.0K
Q4 24	$72.0K
Q1 25	$231.0K
Q2 25	$152.0K
Q3 25	$244.0K
Q4 25	$314.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+66.1%
Q2 22	—	+18.6%
Q3 22	—	+29.6%
Q4 22	—	+35.1%
Q1 23	—	+33.4%
Q2 23	—	+47.6%
Q3 23	—	+46.5%
Q4 23	—	+13.7%
Q1 24	—	+6.3%
Q2 24	—	-9.8%
Q3 24	—	-19.3%
Q4 24	—	+11.3%
Q1 25	—	+3.0%
Q2 25	—	+844.7%
Q3 25	—	-1.4%
Q4 25	—	+14.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$3M	—
Q4 22	$4M	—
Q1 23	$4M	—
Q2 23	$4M	—
Q3 23	$3M	—
Q4 23	$2M	—
Q1 24	$3M	—
Q2 24	$3M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$0	—
Q3 25	$8M	—
Q4 25	$9M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$15M	$8M	—
Q2 22	$15M	$6M	—
Q3 22	$17M	$7M	—
Q4 22	$17M	$8M	—
Q1 23	$22M	$9M	—
Q2 23	$24M	$8M	—
Q3 23	$28M	$8M	—
Q4 23	$21M	—	$6M
Q1 24	$24M	$8M	—
Q2 24	$22M	$7M	—
Q3 24	$22M	$7M	—
Q4 24	$25M	—	$5M
Q1 25	$27M	$7M	—
Q2 25	$261M	$2M	—
Q3 25	$14M	$14M	—
Q4 25	$19M	$27M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$90M	$92M	$182M
Q2 22	$63M	$88M	$151M
Q3 22	$61M	$75M	$136M
Q4 22	$58M	$173M	$230M
Q1 23	$42M	$168M	$210M
Q2 23	$32M	$155M	$187M
Q3 23	$45M	$115M	$160M
Q4 23	$31M	$106M	$137M
Q1 24	$45M	$63M	$107M
Q2 24	$76M	$10M	$86M
Q3 24	$53M	$10M	$63M
Q4 24	$82M	$10M	$92M
Q1 25	$50M	$10M	$60M
Q2 25	$193M	$10M	$203M
Q3 25	$160M	$10M	$170M
Q4 25	$396M	$59M	$455M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	2M	+1.0%	+67.5%
Q2 22	2M	+0.4%	+1.6%
Q3 22	2M	+1.5%	+2.9%
Q4 22	2M	+22.3%	+25.9%
Q1 23	3M	+42.5%	+77.7%
Q2 23	3M	+1.2%	+79.1%
Q3 23	3M	+0.9%	+77.9%
Q4 23	3M	+0.4%	+46.0%
Q1 24	3M	+0.2%	+2.7%
Q2 24	3M	+0.4%	+1.9%
Q3 24	3M	+0.2%	+1.3%
Q4 24	3M	+0.4%	+1.2%
Q1 25	6M	+81.7%	+83.5%
Q2 25	6M	+0.4%	+83.4%
Q3 25	7M	+6.7%	+95.2%
Q4 25	10M	+47.7%	+187.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	135
Q2 22	$0	135
Q3 22	$0	135
Q4 22	$0	133
Q1 23	$0	133
Q2 23	$0	133
Q3 23	$0	133
Q4 23	$0	168
Q1 24	$0	168
Q2 24	$0	168
Q3 24	$0	168
Q4 24	$0	159
Q1 25	$0	159
Q2 25	$0	159
Q3 25	$0	159
Q4 25	$0	250

Revenue / Employee